Edwards Lifesciences Stock News

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Drink Some TEA

Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.

Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

Analysts have provided the following ratings for Edwards Lifesciences (NYSE: EW ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 8 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 4 0 0 0 3M Ago 0 3 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Edwards Lifesciences. The company has an average price target of $134.78 with a high of $148.00 and a low of $126.00. Below is a summary of how these 9 analysts rated Edwards Lifesciences over … Full story available on Benzinga.com

Analysts have provided the following ratings for Edwards Lifesciences (NYSE: EW ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 8 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 4 0 0 0 3M Ago 0 3 0 0 0 According to 9 analyst offering 12-month price targets in the last 3 months, Edwards Lifesciences has an average price target of $134.78 with a high of $148.00 and a low of $126.00. Below is a summary of how these 9 analysts rated Edwards Lifesciences over the past 3 months. The greater the number of bullish ratings, the … Full story available on Benzinga.com

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE: SYK ) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to year-ago quarter EPS of $2.81. At the moment, the stock has a 52-week-high of $281.16 and a 52-week-low of $227.84. Stryker closed at $254.34 at the end of the last trading period. For Edwards Lifesciences Corp (NYSE: EW ), Bernstein upgraded the previous rating of Market Perform to Outperform. Edwards Lifesciences earned $0.51 in the fourth quarter, compared to $0.50 in the year-ago quarter. At the moment, the stock has a 52-week-high of $131.73 and a 52-week-low of $78.44. Edwards Lifesciences closed at $106.15 at the end of the last trading period. According to Morgan Stanley, the prior rating for KE Holdings Inc (NYSE: BEKE ) was changed from Equal-Weight to Overweight. KE Holdings earned $0.01 in the fourth quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $72.49 and a 52-week-low of $7.31.

Wednesday afternoon''s top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.

Shares of Edwards Lifesciences Corp. rallied 3.81% to $106.15 Tuesday, on what proved to be an all-around great trading session for the stock market, with…

If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE: EW ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term … Full story available on Benzinga.com

SAN FRANCISCO , March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Central Venous Catheters (CVCs) - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 7; Released: February 2022 Executive Pool: 4019 Companies: 61 - Players covered include Amecath; AngioDynamics Inc.; B. Braun Melsungen AG; Bactiguard AB; Becton, Dickinson and Company; COOK MEDICAL LLC; Edwards Lifesciences Corporation; Guangdong Baihe Medical Technology Co., Ltd; ICU Medical, Inc.; Insung Medical Co.

Medtech companies are being negatively impacted by the rise in energy and commodity costs caused by the ongoing conflict between Ukraine and Russia, Hammerstone Markets said.

IHI: A Standout Performer With Equally Strong Future Growth Prospects